Northern Ireland: MS pill Gilenya funded
Published date: 28 Nov 2012 at 4:55PM
Gilenya is now being funded by Department of Health, Social Services and Public Safety (DHSSPSNI) for the treatment of adults with highly-active relapsing MS in Northern Ireland.
The recent decision means that people with MS who have regular relapses or increased relapse rates (compared to the previous year), despite taking beta interferon, will be eligible for the treatment.
Funding for new patients
The treatment was approved by the SMC for people with MS in Scotland in September and by NICE in April for people in England and Wales.
The DHSSPSNI endorsed the NICE recommendation for Gilenya earlier this year, but since then the treatment has only available to a limited number of a patients. This newly published commissioning plan outlines funding for around 30 new patients per annum.
Improving quality of life
Patricia Gordon, Director of the MS Society in Northern Ireland, said:
“We welcome the announcement that Gilenya will now be funded for at least 30 new patients. It is a significant step forward and increases the treatment options for people with highly active relapsing remitting MS.
"Until now, people with MS have received their medicines via injection or infusion only, so the opportunity to take a daily tablet instead is a significant step forward and for some, will greatly improve their quality of life."
The opportunity to take a daily tablet is a significant step forward and for some, will greatly improve their quality of life.Patricia Gordon, Director of the MS Society in Northern Ireland